Since taking office for the second time, President Trump’s Administration has brought high prescription drug pricing and U.S. healthcare spending center stage. The recent effort to curb the rising costs of prescription medication and deliver most-favored-nation (MFN)* pricing to U.S. consumers is taking shape through a much shorter name: TrumpRx.

TrumpRx is characterized by two key pillars:

  • A government-run website (TrumpRx.gov) to steer patients to pharmaceutical manufacturers’ direct-to-consumer (DTC) websites offering prescription drugs at lower costs
  • Trade (tariff) and pricing tactics to entice drug manufacturers to take specific actions (including agreeing to reduced, negotiated pricing and investing in U.S. manufacturing infrastructure) in exchange for financially relevant benefits

The TrumpRx.gov website (which will be explored in more detail below) is just one part of this Administration’s strategy to reduce prescription medicine costs for U.S. consumers. The second component of the TrumpRx strategy includes “carrots and sticks” — awarding financial incentives for drug manufacturers choosing to participate and delivering trade and cost penalties (tariffs and fees) to companies that do not.

Under TrumpRx, prescription drug manufacturers must agree to:

  • Provide MFN prices to every single Medicaid patient.
  • Not offer other developed nations better prices for new drugs than prices offered in the U.S.
  • Offer medication at a price no higher than the best price available in developed nations.
  • Reinvest any increased revenues achieved abroad into lowering prices for American patients and taxpayers.
  • Invest in U.S. manufacturing, production and supply chain.

In exchange for participation in TrumpRx, the Trump Administration has promised to:

  • Provide manufacturers with an avenue to cut out middlemen (Pharmacy Benefit Managers, also known as PBMs) and sell medicines directly to patients via TrumpRx.gov.
  • Use trade policy to support manufacturers in raising prices internationally.
  • Allow multi-year exemptions from certain tariffs on pharmaceutical imports.

Interestingly, public awareness of TrumpRx is particularly low. A November KFF Health Tracking Poll reports that most adults (59%) have heard “nothing at all” about TrumpRx. Of those who are aware, 62% percent say it is either “not too” or “not at all likely” that people like them will see reduced prescription drug costs. Four in ten believe they are “very” or “somewhat likely” to experience a lower prescription drug spend.

Announcements and plans can shine a light on intent but do not represent finalized policies. TrumpRx is evolving. An expected “full launch” in early 2026 will likely illuminate more detailed information and a broader awareness of how TrumpRx will impact American consumers.

TrumpRX for Prescription Weight Loss Drugs

What is the purpose of TrumpRx? And why now?

According to the White House Fact Sheet on MFN pricing (posted on November 6), “President Trump is taking decisive action to rebalance a system that has allowed pharmaceutical manufacturers to offer low prices to other wealthy nations while charging Americans significantly higher prices.”

The following data is highlighted in the Fact Sheet:

  • Americans pay more than three times the price for brand-name drugs than other nations pay, even after accounting for manufacturer discounts.
  • The U.S. accounts for roughly 75% of global pharmaceutical profits, despite accounting for less than 5% of the world’s population.
  • The U.S. government provides research subsidies and a significant healthcare spend with pharmaceutical drug manufacturers, yet Americans are paying higher costs for the drugs produced.

It’s no secret that prescription drug prices and medication costs in the U.S. have risen sharply in the past few years, directly impacting everyday consumers. For some patients, their medications have become completely unaffordable. Spiking prescription drug costs are also significantly burdensome for commercial health plans, employers and the government-run health plans of Medicare and Medicaid.

Recent data from KFF, a nonpartisan health policy research organization further highlights the rising prescription drug cost challenge:

Blame for higher prices has recently been placed on the mark-up and rebate strategies deployed by Pharmacy Benefit Managers (PBMs), insurance structures, pharmaceutical manufacturers themselves and other players operating within the complex healthcare/insurance dynamic. Of course, the reality is that no one party or player deserves all the heat.

Rising cost pressures, medical inflation, a changing payer mix and the broader costs of health innovation compound the pricing challenges facing consumers. Despite the causes of rising healthcare and prescription drug costs, the need for seismic change across the U.S. healthcare and insurance industries is undeniably urgent — and further compounded by tight timing. Congress was unable to come to an agreement about extending subsidies which expired as of December 31, 2025. Millions of Americans who access health insurance through the Affordable Care Act (ACA) may see their premiums double in 2026.

How might TrumpRx directly impact consumers?

Widespread adoption of GLP-1 for weight loss and weight management has literally transformed the pharmaceutical landscape in just a few short years. As per the 2025 Pharmacy in Focus report by the Evernorth Research Institute, GLP-1s accounted for 46.8% of the total increase in drug spending with a whopping 148.7% increase in net trend across 2024. Ozempic and Wegovy account for the highest annual prescription drug expenditures in the U.S.

Initial TrumpRx agreements with pharmaceutical manufacturers Eli Lilly and Company and Novo Nordisk were announced in November, with a focus on Ozempic and Wegovy. Ozempic and Wegovy (both Glucagon-Like Peptide-1 medications — GLP-1s) are intended to treat adults struggling with chronic conditions including diabetes, heart disease and obesity.

Because of the recent surge in GLP-1 use and cost, some commercial health plans are now excluding these types of drugs from their plans or limiting coverage to individuals with specific health diagnoses. States are ironing out their specific responses to GLP-1 drug coverage for Medicaid participants as well.

For example, the state of North Carolina discontinued Medicaid coverage of GLP-1s for obesity in October 2025. Despite anticipated TrumpRx price cuts for GLP-1s, California ended Medicaid coverage for weight-loss drugs as of January 1, 2026. The exact impacts to specific consumers are not crystal clear.

TrumpRx.gov: A government-run website connecting consumers to pharmaceutical companies’ direct-to-consumer (DTC) purchasing options

According to the TrumpRx.gov website, TrumpRX “doesn’t sell medications. Instead, it connects patients directly with the best prices, increasing transparency and cutting out costly third-party markups.” The website is intended for use by cash-paying individuals who want (or need) access to discounted medication and also for beneficiaries of Medicaid (the federal government insurance program for lower-income adults and children). Participating prescription drug manufacturers listed on TrumpRx.gov must agree to offer medication on their DTC website with MFN pricing. The TrumpRx.gov website is expected to be populated with more details in January 2026.

Pharmaceutical companies’ DTC websites allow consumers to purchase prescription drugs without using their health insurance benefits. They are also a go-to option for consumers whose insurance plan does not cover a specific medication. TrumpRx.gov is expected to serve as the centralized portal for consumers to easily browse DTC websites and compile cost-comparison information. Broader visibility into prescription drug prices and alternative purchasing options would certainly prove convenient and useful to any cost-conscious consumer. Awareness empowers consumers to make informed decisions. And, as consumers of all ages grow increasingly comfortable shopping online for just about everything, accessing prescription medications along the same path may make sense.

However, DTC programs and pricing may not necessarily be lower than what is offered through commercial insurance plans. For example, a White House Fact Sheet specifically mentions that the drug Xeljanz will be available at a 40% discount as part of TrumpRx. Xeljanz is covered by many commercial insurance plans at an estimated 50% to 55% discount after and including rebates. Specific impacts will become clearer as additional manufacturers sign on to participate in TrumpRx and as full pricing details are published online.

What kinds of drugs or brands are part of TrumpRx?

Under TrumpRx, a patient’s expected monthly spend for Ozempic and Wegovy may drop from list prices of $1,000 per month to $350 per month. The monthly cost of Zepbound (an injectable prescription medicine that may help adults with obesity) may fall from $1,086 per month to $346 per month.

Such sharp savings will provide immediate, life-changing relief for many consumers hoping to prevent and/or manage diabetes and use GLP-1s as part of a comprehensive weight management program.

Migraine medications, including Emgality, and drugs like Xeljanz (to treat autoimmune diseases including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis) are included as part of TrumpRx. Emgality may be offered at up to $444 off of the list price, and, according to the White House’s September 30 Fact Sheet, Xeljanz will be available at a 40% discount to patients purchasing directly. EMD Serono (the U.S. and Canadian subsidiary of Germany-based Merck KGaA) will offer its full portfolio of in vitro fertilization (IVF) therapies at reduced prices through TrumpRx.

An agreement with Mark Cuban-owned Cost Plus Drugs will provide TrumpRx access to its application programming interface for real-time visibility into pricing. This emerging partnership illustrates the power of public-private partnerships and the use of data to cultivate broader consumer awareness and competition.

While TrumpRx may offer unprecedented financial relief, effectively managing chronic conditions like obesity, diabetes and migraines still requires personalized medical guidance and a longer-term relationship with a primary care provider or licensed healthcare practitioner. It’s important to mention that having affordable access to medication does not mean that patients should manage and monitor their prescription medication without medical oversight from a trained professional. Guidance and responsive support is an important piece of the puzzle for patients seeking progress and long-term, lasting change.

GLP-1 prescription drugs for weight management, diabetes treatment and chronic disease prevention

According to the Centers for Disease Control and Prevention (CDC), over 40% of American adults struggle with obesity — a key driver for conditions like Type 2 diabetes, heart disease and hypertension. The recent spotlight on GLP-1s to prevent and treat such conditions has certainly contributed to a spike in usage across all demographics. As per a November 2025 KFF Health Tracking Poll, 20% of adults report having ever taken a GLP-1 agonist, including the 12% currently taking this type of medication.

TrumpRx to cut GLP-1 costs and expand access and coverage through Medicare

TrumpRx aims to make GLP-1s more affordable and accessible. Also according to the same KFF Health Tracking Poll cited above, most GLP-1 users say their insurance covered at least some of the cost, over half (56%) report that GLP-1 drugs were “difficult” to afford. About a quarter (27%) of GLP-1 users report having insurance but paying the entire cost of the medication themselves. The majority of adults who have taken GLP-1s obtained them from their primary health care provider or a specialist (76%). GLP-1 drugs can be accessed through a traditional pharmacy and are also widely available via telehealth platforms, online providers or websites.

Many popular GLP-1 brands can be purchased directly from pharmaceutical manufacturers’ DTC websites. Along with allowing commercially-insured individuals to purchase GLP-1s outside of their coverage via a “cash pay” option, the “historic reduction” in negotiated prices under TrumpRx will enable Medicare to cover obesity drugs (including Ozempic, Wegovy, Mounjaro and Zepbound) at dramatic discounts. Medicare beneficiaries seeking GLP-1s can expect a flat monthly co-pay of $50.

In general, any means to help maintain a healthier weight and prevent weight-related chronic conditions and high-cost catastrophic events (such as heart attacks and cancer, to name a few) are viewed as a critical step toward a healthier nation. Any measurable public health impacts of expanded access to GLP-1s — and resulting cost savings to the federal government, health plans and individuals — will become clearer in the years ahead.

GLP-1 innovation, progress and new developments

Promoting broader coverage and patient accessibility may encourage manufacturers to innovate in the weight management space. For example, Novo Nordisk’s Wegovy hit the market on January 5 as “the first and only GLP-1 weight-loss medication pill” and a daily GLP-1 pill from Eli Lilly is in late-stage approval.

Daily pills (and needle-free option) may be clinically effective alternatives to injections. In fact, Eli Lilly’s pill is expected to net “$2 billion in sales by the end of 2026, $9 billion by the end of 2027 and $16 billion by the end of 2028.” Oral drugs (once approved) may be significantly cheaper than injectables from the jump — anticipated at just $149 per month for everyone as part of TrumpRx.

GLP-1s are not the silver bullet for weight loss

Weight Watchers describes prescription weight-loss medication not as the “easy way out” but instead as a “different way in.” Millions of Americans truly need a “different way” to manage their weight and prevent more costly and life-limiting chronic conditions from arising. Relying solely on TrumpRx and updates to GLP-1 affordability — without integrating appropriate medical care, social support, dietary changes and lifestyle modifications — is not an ideal strategy.

When it comes to GLP-1 use for weight management, understanding the litany of routes and options — from low-cost monthly prescription “clubs” to compounded GLP-1 microdosing — can become completely overwhelming. The path to long-term weight loss and improved physical health should not be traveled alone.

The team at Valley Integrated Urgent Care & Wellness Center is trained and ready to develop realistic, comprehensive weight-management plans for our patients. Our GLP-1 nutrition program includes lifestyle changes, nutrition counseling, prescription drug management and monitoring. Affordable GLP-1 medication prices through TrumpRx and realistic support through a personalized weight management program might be just the ticket for long-term weight loss and overall wellbeing.

Schedule an in-person or virtual Weight Loss Consultation with one of the doctors at Valley Integrated Urgent Care & Wellness Center. If you choose to use GLP-1s as part of your plan, we can help you secure appropriate GLP-1 medication and you will also have access to:

  • Personalized dosing plan developed with your doctor
  • Medical supervision throughout your journey
  • Expert guidance on maximizing your results
  • Ongoing support from our weight management team to help you make long-term lifestyle changes that matter across your lifespan

Resources: A condensed timeline of TrumpRx activity and related policies, rules, acts and orders

* Most Favored Nations (MFN) include: Canada, France, Germany, Italy, Japan, the United Kingdom, Switzerland and Denmark. These countries have greater purchasing power and demand lower prescription drug prices than ordinary consumers purchasing individually. Pharmaceutical companies tend to sell their drugs at a much lower price to other countries than they do to consumers in the U.S. because MFNs buy medicines in large quantities. To date, the purchasing power enjoyed by other developed countries has not been leveraged in the States, as the U.S. does not have a national health service and the federal government does not buy medicines in bulk.

Disclaimer

Information contained within this article has been obtained from publicly available reports, articles and documents. While the information has been diligently researched and verified to ensure the integrity of content at the time of publication, Valley Integrated Urgent Care & Wellness Center does not certify or guarantee accuracy or completeness. Priorities, announcements, and legislation related to this topic are continually changing and evolving. This article is provided for general informational purposes only and should not be construed as a substitute for personalized advice from a qualified healthcare provider. The authors and publishers of this article disclaim any liability for any actions taken or decisions made based on the information presented herein. For the most up-to-date information on TrumpRx, visit www.whitehouse.gov or
trumprx.gov. All products, brands and names included in this article are the property of their respective owners.

Categories

Categories

Recent Post